Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01665352 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by vTv Therapeutics.

Completed
Registry status
Phase 2
Development phase
186
Enrollment target
19
Study locations

NCT01665352 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by vTv Therapeutics. The registered enrollment target is 186 participants, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (93% lower). The trial reports 19 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01665352, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by vTv Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
186 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG TTP054

Study Locations (19)

Texas

  • Site 16 - Dallas
  • Site 10 - Houston
  • Site 2 - Houston
  • Site 11 - Katy

California

  • Site 18 - Chula Vista
  • Site 1 - Los Angeles

Florida

  • Site 4 - Coral Gables
  • Site 5 - Port Orange

Colorado

  • Site 13 - Denver

Hawaii

  • Site 3 - Honolulu

Indiana

  • Site 17 - Indianapolis

Kentucky

  • Site 7 - Louisville

Maine

  • Site 8 - Auburn

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2012-08
Est. Completion 2013-05
Phase Phase 2

Sponsor

vTv Therapeutics

13 total trials

What the Registry Record Tells You About NCT01665352

The ClinicalTrials.gov registry entry for NCT01665352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (93% lower). The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01665352 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT01665352 about?

NCT01665352 is a clinical study titled "A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes". The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.

What is the current status of trial NCT01665352?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2012-08. Estimated completion is 2013-05.

What conditions does trial NCT01665352 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT01665352?

The interventions under investigation include: Placebo (DRUG), TTP054 (DRUG).

Who is sponsoring clinical trial NCT01665352?

This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01665352 being conducted?

This trial has 19 study locations across California, Colorado, Florida, Hawaii, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.